We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden.
Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.
Our lead drug candidate, fexuprazan, is anticipated to enter Phase 3 clinical development in the US in 2022 to evaluate its safety and efficacy for the treatment of erosive esophagitis (EE), a chronic and potentially progressive condition that impacts millions of patients in the US. EE is caused by a recurring reflux of acidic stomach contents into the esophagus over time. Fexuprazan is a potassium-competitive acid blocker (P-CAB) designed to block proton pumps from secreting gastric acid in the stomach.
NG101 is a dopamine D2 receptor antagonist in late-stage development for the treatment of gastroparesis, a severe and debilitating GI disorder that affects the daily lives of as many as 10 million people in the US. Gastroparesis is a common complication of diabetes, but there is also a significant idiopathic population who suffer from the same constellation of symptoms. NG101 is being developed with the goal to provide a safe and effective first-line therapy for patients with gastroparesis. NG101 is currently in a Phase 2 clinical development in the US.